[Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma].
Eighty-one adult patients with bronchial asthma who suffered asthmatic episodes in spite of treatment with 400 mg/day of BDP were placed on pranlukast therapy for 4 weeks. Group I, which showed a 5% or greater increase in PEFR, continued oral pranlukast medication for an additional two years. Those patients who did not show an increase of 5% or greater in PEFR after 4 weeks of pranlukast therapy were instructed to continue the medication for another year. Group II, which exhibited a 5% or greater increase in PEFR after a one-year period continued medication for one more year. Medication was suspended for Group III, which failed to show improvement in PEFR after one year, and the group was placed under observation for the following year. Group I improved significantly in PEFR and exhibited a reduction in the frequency of b2 inhalation, the number of night visits to a medical facility, the amount of steroids inhaled, and the quantity of oral steroids given at regular intervals; and the Group I peripheral eosinophil count, serum ECP level, and FEV1.0 ameliorated. After one year, Group II also showed significant improvement in PEFR and a reduction in both the peripheral eosinophil count and the serum ECP level. This group's PEFR continued to improve after two years. One year after medication was suspended, Group III showed a significant increase in the number of night visits to a medical facility and a rise in the serum ECP level. These findings indicated the efficacy of pranlukast.
Horiguchi
Takahiko
T
Department of Internal Medicine, Fujita Health University Second Hospital, 3-6-10 Otobashi, Nakagawa-ku, Nagoya, 454-8509, Japan.
Kondo
Rieko
R
Miyazaki
Junici
J
Shiga
Mamoru
M
Sugiyama
Masahiro
M
Hirose
Masahiro
M
Tachikawa
Soichi
S
D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001507:Beclomethasone / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins; D002867:Chromones / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D047091:Eosinophil Granule Proteins; D004804:Eosinophils; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D020024:Leukotriene Antagonists / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D012260:Ribonucleases / Q000097:blood; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D015415:Biomarkers; D001798:Blood Proteins; D002867:Chromones; D047091:Eosinophil Granule Proteins; D020024:Leukotriene Antagonists; D012260:Ribonucleases; D001507:Beclomethasone; C047681:pranlukast